Heartbeam, Inc.

Greetings and welcome to the HeartBeam First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. Before we begin the formal presentation, I would like to remind everyone that statements made on this call and webcasts may include predictions, estimates, or other information that might be considered might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of the presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements. in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions. You should also review our most recent Form 10-K and Form 10-Q for a more complete discussion of these factors and other risks, particularly under the heading Risk Factors. A press release detailing these results crossed the wires this afternoon and is available in the in the investor relations section of our company's website, heartbeam.com. Your host today, Bronislav Vytautas, Chief Executive Officer and Founder, Rob Eno, President, and Rick Bronstein, Consulting Chief Financial Officer, will present results of operations for the first quarter ended March 31, 2024. At this time, I will turn the call over to Heartbeam Chief Executive Officer, Bronislav Vytautas.

Please go ahead.

Thank you, operator. I'd like to start by giving a brief overview of Harbin and our technology. It is important to understand how our VECG technology is different and vastly more powerful than the most common personal ECG technologies that are on the market today. K12 lead ECG is one of the most commonly performed diagnostic tests in the standard is hospitals and clinics. There are many ECG technologies that can be used by patients or consumers at home. You can see a couple of examples on this slide on the right-hand side. They're not valid ECG technologies. Instead, they are one-lead, three-lead, or six-lead ECGs. This is adequate for detecting many arrhythmias, but is not sufficient to detect a heart attack or complex arrhythmias. In contrast, a HeartBeam Amigo is an easy-to-use credit card-sized system that synthesizes the 12-ADC gene. The key aim of HeartBeam technology is to quickly and accurately help clinicians identify the full range of cardiac conditions, including a heart attack, outside of a medical institution. The Amigo device, coupled with a smartphone app and cloud-based diagnostic software, facilitates remote evaluation of cardiac symptoms by physicians, and we believe it could reduce the critical time to intervention for heart attack patients. Shortening that time from symptoms to the door of a medical facility would reduce complications and save many lives. An effective triage tool in the hands of patients could also reduce the number of unnecessary emergency room visits and reduce costs to the health care. So why do we think that an easy to use 12 lead ECG with patients is transformational? First, having the ability for patients to take frequent 12 lead ECG readings over time and in a variety of real life settings potentially has huge diagnostic value. Whenever a patient is feeling symptoms, they can get the 12 lead reading that will be reviewed by a physician. Secondly, trending or 12 EDCGs, both symptomatic and asymptomatic over time, will allow the physicians to gain insight to help guide cardiac care. Frequent 12 EDCGs create a trending and insightful way of tracking a cardiac condition. Finally, combining deep learning algorithms with a large number of studentally collected VECGs has the potential to create an unsurpassed predictive and diagnostic algorithm. We have the opportunity to address not only the arterial fibrillation market, but also the coronary artery disease market, which is six times larger. In the United States, there are approximately 3 million AP patients representing a $2 billion market. There are approximately 20 million coronary artery disease patients, which is a $12 billion market. So the overall opportunity in the U.S. only is about $14 billion. I'd like to now turn the call over to our President, Robby.